Epigral Limited (BOM:543332)
India · Delayed Price · Currency is INR 1,829.95
-124.00 (-6.35%)
At close: Aug 4, 2025
Sage Therapeutics Revenue
In the fiscal year ending March 31, 2025, Epigral had annual revenue of 25.50B INR with 32.19% growth. Epigral had revenue of 6.28B in the quarter ending March 31, 2025, with 19.63% growth.
Revenue
25.50B
Revenue Growth
+32.19%
P/S Ratio
3.15
Revenue / Employee
23.37M
Employees
1,072
Market Cap
78.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 25.50B | 6.21B | 32.19% |
| Mar 31, 2024 | 19.29B | -2.59B | -11.84% |
| Mar 31, 2023 | 21.88B | 6.37B | 41.10% |
| Mar 31, 2022 | 15.51B | 7.22B | 87.18% |
| Mar 31, 2021 | 8.29B | 2.19B | 35.89% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,840.87B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,429.39B |
| Infosys | 1,672.76B |
| Hindustan Unilever | 639.28B |